Login to Your Account


BOSTON – Concerns about the impact President Donald Trump's administration is having on the practice and standing of science are at the top of the agenda at this year's AAAS meeting.

Valeant Pharmaceuticals International Inc. won a widely anticipated FDA approval for its moderate to severe plaque psoriasis drug, Siliq (brodalumab), complete with an expected black box warning for suicidal ideation and behavior that analysts expect could hamper sales.

Merck & Co. Inc. is calling a halt to a high-profile phase II/III study of verubecestat after data monitors found "virtually no chance of finding a positive clinical effect" for patients with mild to moderate Alzheimer's disease.

More U.S. Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: